Investigating how mycobacteria manage protein quality and stress responses
Official title: Phosphoarginine-linked protein quality control and stress responses in mycobacteria
Funded at University of Delaware · NIH-10803457 · Data updated 2026-11-12
This study is looking at how the bacteria that cause tuberculosis handle stress and fix damaged proteins, with the hope of finding new ways to create antibiotics that can help people with drug-resistant tuberculosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Delaware NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | August 15, 2024 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $346,677 |
| NIH project number | 1R01AI171196-01A1 |
| Project ID | NIH-10803457 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with drug-resistant tuberculosis or those at high risk of developing such infections.
✕Less likely to help
Patients with non-tuberculosis bacterial infections or those who do not have antibiotic-resistant strains may not benefit from this research.
What this research studies
This research focuses on understanding how mycobacteria, particularly Mycobacterium tuberculosis, respond to stress and manage protein quality through a specific mechanism involving arginine phosphorylation. The study aims to explore the role of Clp proteases, which are crucial for degrading damaged proteins, and how these processes can be targeted to develop new antibiotics. By examining the conditions that trigger these responses, the research seeks to identify novel therapeutic targets that could lead to effective treatments against drug-resistant tuberculosis. Patients may benefit from this research as it could pave the way for new antibiotics that are effective against resistant strains of tuberculosis.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antibiotics that effectively combat drug-resistant tuberculosis.
How similar studies have gone: Other research has shown promise in targeting proteases for antibiotic development, indicating that this approach could yield significant advancements.
Where this research is happening
-
University of Delaware
Newark, United States Active
Researchers
- Principal investigator: Schmitz, Karl Robert — University of Delaware
- Study coordinator: Schmitz, Karl Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.